Generate Biomedicines has raised $400m in one of the largest biotech initial public offerings (IPO) since 2024, signalling renewed investor appetite for drug developers making the public jump. Generate, an AI drug discovery specialist, has priced 25 million shares at $16 each. The $400m could be bolstered by a further $60m if underwriters exercise their option to buy an additional 3.75 million shares at the same price. Generate’s stock will hit the Nasdaq Global Select Market

Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. Under the leadership of CEO Marianne De Backer, Ph.D., Vir is trading a stake in its PSMA-targeted bispecific VIR-5500 for a $335 million upfront and near-term capital infusion from Astellas. The PSMAxCD3 bispecific leverages Vir’s PRO-XTEN dual-masking technology, which is designed to keep the therapy in

SOMERVILLE, Mass., February 23, 2026 /GLOBE NEWSWIRE/ Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, its lead in vivo gene editing program. TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygou